glp·helper
glphelper.com/wegovy/texas/north-richland-hills
GLP-1 receptor agonistFDA-approved June 2021Rx · Subcutaneous injection · Once weekly

Wegovy® providers &
prescriptions in North Richland Hills, TX

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians near North Richland Hills, TX from the federal NPI registry. Ask each office whether it prescribes Wegovy.[9]

average Wegovy weight loss →trial-anchored estimate
city providers
25
as of today

Same molecule (semaglutide): Ozempic in North Richland Hills, Semaglutide in North Richland Hills

Other GLP-1 medicines: Tirzepatide in North Richland Hills, Mounjaro in North Richland Hills, Zepbound in North Richland Hills

§ 02Provider directory: Texas
25 of 25 shown

Find a Wegovy provider in North Richland Hills.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Wegovy by Texas town, physicians per town
§ 03Getting Wegovy in North Richland Hills
25 providers · North Richland Hills, TX

How to get Wegovy in North Richland Hills.

25 GLP-1 prescribers and 6 local resource types are on record for North Richland Hills, plus 3 nearby towns in the directory.

Physicians in North Richland Hills
25 physicians
25 physicians from the federal NPI registry in North Richland Hills, most listed as Family Medicine (14), Internal Medicine (9) and Family Medicine, Sports Medicine (1). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Hurst (19 providers), Haltom City (6 providers) and Bedford (28 providers).
Around the prescription in North Richland Hills
6 listed nearby
6 dietitians, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near North Richland Hills.
Medicaid (weight loss)
Diabetes only
As of April 2026, Texas Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Texas’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Ozempic, higher dose.

Wegovy is the brand name for semaglutide at the higher 2.4 mg dose. It is the same molecule as Ozempic, marketed by the same manufacturer for a different FDA-approved indication. It is a once-weekly subcutaneous injection in the GLP-1 receptor agonist class.[2][3]

In the STEP-1 randomized trial, 68 weeks of weekly 2.4 mg semaglutide produced a mean body-weight reduction of 14.9%, roughly 2.5× the weight loss seen at the Ozempic 1 mg dose. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity such as hypertension or dyslipidemia.[1]

Bar chart of Wegovy dose strengths on the FDA label: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg
Wegovy comes in 6 strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg, 7.2 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceNDC 0169-4525
Active ingredient
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
June 2021
Approved use
Chronic weight management in adults with obesity or overweight with weight-related comorbidities
Off-label use
Off-label use is uncommon. Ozempic is the FDA-approved formulation for type 2 diabetes
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 1.7 mg · 2.4 mg · 7.2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in North Richland Hills

North Richland Hills, Texas has a population of 69,917 people. The adult obesity rate in North Richland Hills is an age-adjusted estimate of 30.6%, 5 percentage points below the Texas state rate of 35.6%. Diagnosed diabetes reaches 9.3% of adults in North Richland Hills. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 23.6% of adults in North Richland Hills.

of North Richland Hills adults have obesity
30.6%
diagnosed diabetes
9.3%
no regular physical activity
23.6%

Age-adjusted estimates for North Richland Hills, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight lossweight regain after stopping
§ 05Support around Wegovy in North Richland Hills
6 fitness clubs

The prescription is one part. Here is the rest, in North Richland Hills.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near North Richland Hills, TX, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Life Time
FITNESS
4.4 on Google · 879 reviews
10761 Founders Wy
Website
NRH Centre
REC CENTER
4.6 on Google · 839 reviews
6000 Hawk Ave
Website
The Keller Pointe
REC CENTER
4.3 on Google · 590 reviews
405 Rufe Snow Dr
Website
Euless Family Life Center
REC CENTER
4.5 on Google · 420 reviews
300 W Midway Dr
Website
StretchLab
FITNESS
4.9 on Google · 369 reviews
1411 Keller Pkwy #600
Website
Hurst Recreation Center
REC CENTER
4.6 on Google · 336 reviews
700 Mary Dr
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Denise Anderson, C.D.E
RD
Registered dietitian
800 5Th Ave
Call 817-334-1400NPI 1457531493
Joice Carter, R.D
RD
Registered dietitian
800 5Th Ave
Call 817-334-1400NPI 1750462909
Lorin Cheung
RD
Registered dietitian
6749 Marilyn Ln
Call 917-992-2929NPI 1700426681
Rebecca Dority, R.D.L.D
RD
Registered dietitian
1735 Keller Springs Rd
Call 972-242-0185NPI 1659319044
Laila Elnashef
RD
Registered dietitian
8216 Ardilla Ln
Call 716-533-9653NPI 1104797364
Kristin Guhr, RD
RD
Registered dietitian
7501 Oak Park Dr
Call 940-391-2904NPI 1720921083
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize results from the STEP program, the global Phase IIIa trials Novo Nordisk submitted to the FDA for the weight-management indication, and the SELECT cardiovascular outcomes trial. Numbers below are means at the 68-week endpoint, 2.4 mg weekly dose.

STEP-1 randomized 1,961 adults with obesity to weekly 2.4 mg semaglutide vs placebo over 68 weeks. Mean body-weight reduction was 14.9% on semaglutide vs 2.4% on placebo. 86.4% of patients on semaglutide achieved ≥ 5% weight loss vs 31.5% on placebo.[4]
STEP / SELECT endpoint table2.4 mg / 68 wk
Weight change
−14.9%
vs −2.4% placebo, 68 wk[4]
≥ 5% weight loss
86.4%
vs 31.5% placebo[4]
≥ 15% weight loss
50.5%
vs 4.9% placebo[4]
Major adverse cardiac events
−20%
HR 0.80 vs. placebo (SELECT)[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Wegovy weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Wegovy side effects are stomach and gut effects.

In Wegovy's weight trials at 2.4 mg, the most common side effects were nausea (44%), diarrhea (30%), vomiting (24%), and constipation (24%). These rates are higher than at Ozempic doses.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
44%
mild
More common than at Ozempic doses
Diarrhea
30%
mild
Most frequent during dose escalation phase
Vomiting
24%
mild
Slower titration reduces incidence
Constipation
24%
mild
Hydration + fiber recommended
Abdominal pain
20%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; class warning
Gallbladder disease
1.6%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Wegovy costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Wegovy monthly cost by how you pay
Pharmacy retail (no insurance)$1,610 to $1,788per monthBrand-name retail average, May 2026[6]
NovoCare self-pay, pen$349per month0.25 to 2.4 mg. Wegovy HD 7.2 mg is $399. New patients pay $199 for the first two fills of 0.25 or 0.5 mg through Dec 31, 2026
NovoCare self-pay, pill$149 to $299per month1.5 mg $149, 4 mg $199, 9 and 25 mg $299
Commercial insurance (covered)$25 to $400per month copayVaries by PBM; many plans require BMI ≥ 30 + step therapy
Commercial insurance (denied)Typically deniedMost plans exclude weight-loss medications from formulary
Medicare GLP-1 Bridge$50per monthJul 1, 2026 to Dec 31, 2027, Part D enrollees who meet weight and health criteria[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only, up to $100 a month in savings
Find Wegovy providers in North Richland Hills

Physicians from the federal NPI registry. Ask each office whether it prescribes Wegovy.

Wegovy in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Wegovy.

Related GLP-1 research
§ 09Frequently asked: Wegovy in Texas

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

FDA approval is for adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). Adolescents 12+ with a BMI in the 95th percentile or higher were added to the label in December 2022.[1]